{
  "main_header": {
    "sid": 601817,
    "name": "Indoco Remedies",
    "stock_name": "Indoco Remedies",
    "full_name": "Indoco Remedies Ltd",
    "name_url": "stocks-analysis/indoco-remedies",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "251.70",
    "chg": -0.55,
    "chgp": "-0.22%",
    "dir": -1,
    "prev_price": "252.25",
    "mcapval": "2,326.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 532612,
    "symbol": "INDOCO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE873D01024",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "17.67 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/indoco-remedies-601817-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Indoco Remedies Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indoco-remedies-technical-momentum-shifts-amid-mixed-market-signals-3742880",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IndocoRemedies_technicaldot_3742880.png",
        "date": "2025-12-03 08:05:13",
        "description": "Indoco Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition from a mildly bullish trend to a sideways movement, underscoring a period of consolidation amid mixed technical indicator signals."
      },
      {
        "title": "Indoco Remedies: Analytical Perspective Shifts Amidst Challenging Financials and Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/indoco-remedies-downgraded-to-sell-amid-mixed-technicals-and-weak-financials-3740211",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IndocoRemedies_mojoScore_3740211.png",
        "date": "2025-12-02 08:08:05",
        "description": "Indoco Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment driven by evolving technical indicators, valuation considerations, financial trends, and quality metrics. This article explores the factors influencing the recent changes in the company’s evaluation, providing investors with a comprehensive understanding of its current standing amid a challenging market environment."
      },
      {
        "title": "Indoco Remedies Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indoco-remedies-shows-signs-of-technical-momentum-shift-amid-mixed-market-returns-3740112",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IndocoRemedies_technicaldot_3740112.png",
        "date": "2025-12-02 08:06:54",
        "description": "Indoco Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited a subtle shift in its technical momentum, reflecting a nuanced market assessment. Recent evaluation adjustments highlight a transition from mildly bearish to mildly bullish trends, underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages."
      },
      {
        "title": "How has been the historical performance of Indoco Remedies?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-indoco-remedies-3739162",
        "imagepath": "",
        "date": "2025-12-01 22:59:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Trends</strong></p>\n<p>Indoco Remedies’ net sales exhibited a consistent upward trend from ₹968.45 crores in March 2019 to a peak of ₹1,817.29 crores in March 2024. However, the fiscal year ending March 2025 saw a decline to ₹1,664.92 crores, indicating a contraction of approximately 8.4% from the previous year. This dip interrupts a five-year growth streak and may reflect market challenges or operational headwinds.</p>\n<p>Operating profit before depreciation and interest (PBDIT) also followed a similar pattern, rising from ₹76.66 crores in 2019 to a high of ₹329.67 crores in 2022, before falling sharply to ₹104.71 crores in 2025. The operating profit margin correspondingly dropped from 21.77% in 2022 to just 6.05% in 2025, signalling margin pressures.</p>\n<p>Profit after ..."
      },
      {
        "title": "Indoco Remedies Sees Revision in Market Evaluation Amidst Challenging Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/indoco-remedies-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3736814",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndocoRemedies_mojoScore_3736814.png",
        "date": "2025-11-29 17:52:31",
        "description": "Indoco Remedies, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability and cautious investor sentiment, underscoring the complexities facing the company in a competitive industry landscape."
      },
      {
        "title": "Indoco Remedies Faces Financial Strain Amidst Rising Costs and Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/indoco-remedies-financial-trend-improves-from-very-negative-to-negative-despite-ongoing-challenges-3684275",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IndocoRemedies_fintrenddot_3684275.png",
        "date": "2025-11-10 08:00:20",
        "description": "Indoco Remedies reported strong cash reserves and net sales for the quarter ending September 2025, but faced challenges with rising interest expenses and low return on capital employed. The company's high debt-equity ratio and poor debtors turnover indicate financial strain, contributing to its underperformance relative to the Sensex."
      },
      {
        "title": "Are Indoco Remedies latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-indoco-remedies-latest-results-good-or-bad-3680428",
        "imagepath": "",
        "date": "2025-11-07 19:16:52",
        "description": "Indoco Remedies' latest financial results for the quarter ended September 2025 present a complex picture. The company reported net sales of ₹484.67 crores, reflecting a quarter-on-quarter growth of 10.23% and a year-on-year increase of 12.02%. This growth in revenue indicates some resilience in demand for the company's products, suggesting that the formulation portfolio is gaining traction in the market.\n\nHowever, despite this revenue growth, Indoco Remedies continues to face significant challenges in profitability. The company recorded a net loss of ₹7.93 crores, marking its fifth consecutive quarter in loss-making territory. While this loss represents a 77.84% improvement from the previous quarter, it raises concerns about the sustainability of the business model and operational efficiency. The operating profit margin stood at 9.12%, which, while an improvement from the previous quarter's 4.07%, shows a d..."
      },
      {
        "title": "How has been the historical performance of Indoco Remedies?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-indoco-remedies-3676947",
        "imagepath": "",
        "date": "2025-11-06 22:44:11",
        "description": "Answer:\nThe historical performance of Indoco Remedies shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nIndoco Remedies' net sales peaked at 1,817.29 Cr in March 2024 but declined to 1,664.92 Cr by March 2025. The total operating income followed a similar trend, reaching 1,817.29 Cr in March 2024 before dropping to 1,664.92 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline from 254.16 Cr in March 2024 to 104.71 Cr in March 2025, reflecting a decrease in operating profit margin from 13.66% to 6.05%. Profit before tax turned negative at -74.37 Cr in March 2025, a stark contrast to the profit of 135.80 Cr in March 2024. Consequently, profit after tax fell to -77.95 Cr in March 2025 from 97.01 Cr in the previous year. The company's total liabilities increased from 2,144.73 Cr in March 2024 to 2,429.91 Cr in March 2025, while total assets rose to 2,429...."
      },
      {
        "title": "Why is Indoco Remedies falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-indoco-remedies-fallingrising-3676568",
        "imagepath": "",
        "date": "2025-11-06 21:25:19",
        "description": "As of 06-Nov, Indoco Remedies Ltd is experiencing a decline in its stock price, currently at Rs 264.40, which represents a decrease of Rs 8.8 or 3.22%. The stock has been underperforming, having fallen consecutively for the last four days, with a total decline of 5.64% over the past week. Today's trading saw the stock reach an intraday high of Rs 285.6 but also dip to a low of Rs 262.8. The stock is trading below all its moving averages, indicating a bearish trend. Additionally, the company has shown poor long-term growth, with operating profit declining significantly over the past five years, and institutional investors have reduced their stakes, reflecting a lack of confidence in the stock's fundamentals.\n\nIn the broader market context, the stock's performance has been notably worse than the benchmark, with a 1-week return of -5.64% compared to the Sensex's -1.30%. Over the past year, Indoco Remedies has ..."
      }
    ],
    "total": 513,
    "sid": "601817",
    "stock_news_url": "https://www.marketsmojo.com/news/indoco-remedies-601817"
  },
  "announcements": [
    {
      "details": "Indoco Remedies Limited has informed the Exchange regarding a press release dated November 01, 2019, titled \"Approval of Glycopyrrolate ANDAfiled from Indoco's Goa Plant II\".",
      "source": "NSE",
      "caption": "Indoco Remedies Limited - Press Release",
      "datetime": "01-Nov-2019"
    },
    {
      "details": "Indoco Remedies Limited has informed the Exchange regarding 'Publication of Unaudited Financial Results for the quarter and half year ended 30.09.2019 in newspapers'.",
      "source": "NSE",
      "caption": "Indoco Remedies Limited - Updates",
      "datetime": "31-Oct-2019"
    },
    {
      "details": "Indoco Remedies Limited has informed the Exchange regarding a press release dated October 18, 2019, titled \"Indoco s Clinical Research Organisation receives zero 483s from USFDA\".",
      "source": "NSE",
      "caption": "Indoco Remedies Limited - Press Release",
      "datetime": "18-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Indoco Remedies Ltd has declared <strong>10%</strong> dividend, ex-date: 04 Sep 25",
          "dt": "2025-09-04",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Indoco Remedies Ltd has announced <strong>2:10</strong> stock split, ex-date: 17 May 12",
          "dt": "2012-05-17",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Indoco Remedies Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 17 May 12",
          "dt": "2012-05-17",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Indoco Remedies Technical Momentum Shifts Amid Mixed Market Signals

2025-12-03 08:05:13

Indoco Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition from a mildly bullish trend to a sideways movement, underscoring a period of consolidation amid mixed technical indicator signals.

Read More

Indoco Remedies: Analytical Perspective Shifts Amidst Challenging Financials and Mixed Technical Signals

2025-12-02 08:08:05

Indoco Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment driven by evolving technical indicators, valuation considerations, financial trends, and quality metrics. This article explores the factors influencing the recent changes in the company’s evaluation, providing investors with a comprehensive understanding of its current standing amid a challenging market environment.

Read More

Indoco Remedies Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:06:54

Indoco Remedies, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited a subtle shift in its technical momentum, reflecting a nuanced market assessment. Recent evaluation adjustments highlight a transition from mildly bearish to mildly bullish trends, underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages.

Read More

How has been the historical performance of Indoco Remedies?

2025-12-01 22:59:40

Revenue and Profit Trends

Indoco Remedies’ net sales exhibited a consistent upward trend from ₹968.45 crores in March 2019 to a peak of ₹1,817.29 crores in March 2024. However, the fiscal year ending March 2025 saw a decline to ₹1,664.92 crores, indicating a contraction of approximately 8.4% from the previous year. This dip interrupts a five-year growth streak and may reflect market challenges or operational headwinds.

Operating profit before depreciation and interest (PBDIT) also followed a similar pattern, rising from ₹76.66 crores in 2019 to a high of ₹329.67 crores in 2022, before falling sharply to ₹104.71 crores in 2025. The operating profit margin correspondingly dropped from 21.77% in 2022 to just 6.05% in 2025, signalling margin pressures.

Profit after ...

Read More

Indoco Remedies Sees Revision in Market Evaluation Amidst Challenging Financials

2025-11-29 17:52:31

Indoco Remedies, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a period marked by subdued profitability and cautious investor sentiment, underscoring the complexities facing the company in a competitive industry landscape.

Read More

Indoco Remedies Faces Financial Strain Amidst Rising Costs and Market Underperformance

2025-11-10 08:00:20

Indoco Remedies reported strong cash reserves and net sales for the quarter ending September 2025, but faced challenges with rising interest expenses and low return on capital employed. The company's high debt-equity ratio and poor debtors turnover indicate financial strain, contributing to its underperformance relative to the Sensex.

Read More

Are Indoco Remedies latest results good or bad?

2025-11-07 19:16:52

Indoco Remedies' latest financial results for the quarter ended September 2025 present a complex picture. The company reported net sales of ₹484.67 crores, reflecting a quarter-on-quarter growth of 10.23% and a year-on-year increase of 12.02%. This growth in revenue indicates some resilience in demand for the company's products, suggesting that the formulation portfolio is gaining traction in the market. However, despite this revenue growth, Indoco Remedies continues to face significant challenges in profitability. The company recorded a net loss of ₹7.93 crores, marking its fifth consecutive quarter in loss-making territory. While this loss represents a 77.84% improvement from the previous quarter, it raises concerns about the sustainability of the business model and operational efficiency. The operating profit margin stood at 9.12%, which, while an improvement from the previous quarter's 4.07%, shows a d...

Read More

How has been the historical performance of Indoco Remedies?

2025-11-06 22:44:11

Answer: The historical performance of Indoco Remedies shows significant fluctuations in key financial metrics over the years. Breakdown: Indoco Remedies' net sales peaked at 1,817.29 Cr in March 2024 but declined to 1,664.92 Cr by March 2025. The total operating income followed a similar trend, reaching 1,817.29 Cr in March 2024 before dropping to 1,664.92 Cr in March 2025. The company's operating profit (PBDIT) also saw a decline from 254.16 Cr in March 2024 to 104.71 Cr in March 2025, reflecting a decrease in operating profit margin from 13.66% to 6.05%. Profit before tax turned negative at -74.37 Cr in March 2025, a stark contrast to the profit of 135.80 Cr in March 2024. Consequently, profit after tax fell to -77.95 Cr in March 2025 from 97.01 Cr in the previous year. The company's total liabilities increased from 2,144.73 Cr in March 2024 to 2,429.91 Cr in March 2025, while total assets rose to 2,429....

Read More

Why is Indoco Remedies falling/rising?

2025-11-06 21:25:19

As of 06-Nov, Indoco Remedies Ltd is experiencing a decline in its stock price, currently at Rs 264.40, which represents a decrease of Rs 8.8 or 3.22%. The stock has been underperforming, having fallen consecutively for the last four days, with a total decline of 5.64% over the past week. Today's trading saw the stock reach an intraday high of Rs 285.6 but also dip to a low of Rs 262.8. The stock is trading below all its moving averages, indicating a bearish trend. Additionally, the company has shown poor long-term growth, with operating profit declining significantly over the past five years, and institutional investors have reduced their stakes, reflecting a lack of confidence in the stock's fundamentals. In the broader market context, the stock's performance has been notably worse than the benchmark, with a 1-week return of -5.64% compared to the Sensex's -1.30%. Over the past year, Indoco Remedies has ...

Read More

View All News